Parabilis now the largest VC-backed biotech IPO
Parabilis Medicines’ $745M IPO redefines biotech funding—now the largest VC-backed debut in history.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Parabilis Medicines has completed its initial public offering (IPO) on NASDAQ, raising $745 million after upsizing its deal. The company’s shares surged 67% on debut, propelling its market capitalization to $3.7 billion—the largest VC-backed biotech IPO to date. Coverage highlights its focus on targeting previously 'undruggable' diseases, positioning it as a leader in high-risk, high-reward drug development.
Financial and biotech media outlets, including Bloomberg, WSJ, and BioSpace, emphasize the IPO’s record-breaking valuation and the broader market signal it sends. The surge follows a trend of high-profile biotech IPOs, though analysts note the optimism is concentrated in companies with reduced development risk. Watch for investor reactions to Parabilis’ pipeline progress and whether its success spurs more VC-backed biotechs to pursue IPOs.
Coverage also suggests scrutiny of whether the market can sustain valuations for early-stage biotech firms beyond the 'derisked' subset.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (88% supported) Updated 43d ago.
Quick answers
What is Parabilis Medicines’ market cap after its IPO?
Parabilis Medicines’ market cap reached $3.7 billion following its first day of trading on NASDAQ.
How much did Parabilis raise in its IPO?
Parabilis raised $745 million after upsizing its initial public offering.
What distinguishes Parabilis from other biotech IPOs?
Parabilis is noted for targeting 'undruggable' diseases and has become the largest VC-backed biotech IPO to date, signaling confidence in its high-risk, high-reward approach.
Coverage (10)
- 'Going for our own moonshot': Parabilis CEO on biotech's record IPO Endpoints News · 46d ago
- Parabilis Medicines Rings the Closing Bell Nasdaq · 46d ago
- Drugmaker Parabilis Soars 67% After $745 Million IPO, Placement Bloomberg.com · 46d ago
- Parabilis soars to $3.7B market cap after first day on NASDAQ FirstWord Pharma · 46d ago
- Parabilis Medicines Shares Rocket Following Record Biotech IPO WSJ · 46d ago
- Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO MedCity News · 46d ago
- Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs BioSpace · 46d ago
- Parabilis Medicines Announces Pricing of Upsized Initial Public Offering Stock Titan · 46d ago
- Parabilis sets a record with a $670M biotech IPO BioPharma Dive · 46d ago
- Parabilis now the largest VC-backed biotech IPO Yahoo Finance · 46d ago
Topics
Related trends
Nasdaq futures rally ahead of big week of earnings, Fed meeting: Live updates
Nasdaq futures are rallying as investors anticipate a pivotal week featuring major corporate earnings and a Federal Reserve meeting.
Huge News for Rocket Lab Investors
Rocket Lab is garnering significant investor attention as analysts weigh a sliding share price against the company's long-term space economy ambitions.
SpaceX stock got cut in half after joining an industry sell-off already underway: Chart of the Day
SpaceX stock has plummeted by half amid a broader industry sell-off, severely impacting the net worth of Elon Musk.
Wall St falls as tech earnings spark AI spending worries; oil hits $100
Wall Street falls sharply as soaring oil prices and intensifying artificial intelligence spending anxieties rattle global markets.
Stock market today: Dow, S&P 500, Nasdaq sell off as rising oil prices, bond yields, and AI capex weigh
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Google Was a Lifeline for Publishers. Now Some Are Thinking of Cutting It Off.
Reddit stock is sliding as the company considers limiting Google's access to its content ahead of an expiring AI licensing deal.